NCT03086538View on ClinicalTrials.gov

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

January 30, 2020

Study Completion Date

May 25, 2020

Conditions
Colo-rectal Cancer
Interventions
DRUG

Pemetrexed

Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.

DRUG

Tarceva 100Mg Tablet

Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03086538 - Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy | Biotech Hunter | Biotech Hunter